➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
McKesson
Johnson and Johnson
Dow
Harvard Business School

Last Updated: June 25, 2021

DrugPatentWatch Database Preview

DEFINITY RT Drug Profile


Email this page to a colleague

« Back to Dashboard

When do Definity Rt patents expire, and what generic alternatives are available?

Definity Rt is a drug marketed by Lantheus Medcl and is included in one NDA. There are five patents protecting this drug.

This drug has forty-two patent family members in fourteen countries.

The generic ingredient in DEFINITY RT is perflutren. One supplier is listed for this compound. Additional details are available on the perflutren profile page.

DrugPatentWatch® Generic Entry Outlook for Definity Rt

Definity Rt was eligible for patent challenges on July 31, 2005.

Indicators of Generic Entry

< Available with Subscription >

  Get Started Free

Summary for DEFINITY RT
International Patents:42
US Patents:5
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 52
Formulation / Manufacturing:see details
What excipients (inactive ingredients) are in DEFINITY RT?DEFINITY RT excipients list
DailyMed Link:DEFINITY RT at DailyMed
Drug patent expirations by year for DEFINITY RT
Recent Clinical Trials for DEFINITY RT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Kibo NamPhase 2/Phase 3
Thomas Jefferson UniversityEarly Phase 1
National Cancer Institute (NCI)Phase 2

See all DEFINITY RT clinical trials

Pharmacology for DEFINITY RT

US Patents and Regulatory Information for DEFINITY RT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lantheus Medcl DEFINITY RT perflutren INJECTABLE;INTRAVENOUS 021064-002 Nov 17, 2020 RX Yes Yes   Get Started Free   Get Started Free   Get Started Free
Lantheus Medcl DEFINITY RT perflutren INJECTABLE;INTRAVENOUS 021064-002 Nov 17, 2020 RX Yes Yes   Get Started Free   Get Started Free   Get Started Free
Lantheus Medcl DEFINITY RT perflutren INJECTABLE;INTRAVENOUS 021064-002 Nov 17, 2020 RX Yes Yes   Get Started Free   Get Started Free   Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for DEFINITY RT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0712293 C300267 Netherlands   Get Started Free PRODUCT NAME: PERFLUTREN BEVATTENDE LIPIDE-MICROBOLLEN; REGISTRATION NO/DATE: EU/1/06/361/001 20060920
0712293 CA 2007 00027 Denmark   Get Started Free
0712293 SPC/GB07/031 United Kingdom   Get Started Free PRODUCT NAME: PERFLUTREN-CONTAINING LIPID MICROSPHERES; REGISTERED: UK EU/1/06/361/001 20060920
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
AstraZeneca
Merck
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.